Europabio

Rare Paediatric Neurological Diseases: A Focus on Europe
2022-03-23 14:00 - 15:00 (Europe/Brussels)
Rare paediatric neurological conditions are debilitating diseases with significant impact on the daily lives of children and their families. Most rare diseases have neurological symptoms, and about 90% of those affecting children have major neurological effects limiting the ability to achieve key cognitive and physical development milestones.

To highlight policy priorities for improving care, patient outcomes and quality of life, Economist Impact, sponsored by PTC Therapeutics undertook a project to better understand how these disorders affect the lives of patients and their families. The resulting report ‘Rare paediatric neurological diseases: A focus on Europe’ highlights the difficulties in achieving a timely and accurate diagnosis, as well as the numerous challenges to providing adequate care and support. It concludes that policymakers should work, together with other stakeholders, to develop a rare diseases healthcare ecosystem that is sufficiently resourced and organized to enable even the most complex conditions to be assessed and managed expeditiously.

National Associations Council Summit 2022 | Biotechnology: Delivering Europe's Industrial Strategy Across Sectors
2022-03-03 10:00 - 13:30
EuropaBio’s National Associations Council (NAC) is a platform that brings together all EuropaBio’s National Associations and helps to ensure coordination of EuropaBio actions throughout Europe.

The NAC represents biotechnology priorities across Europe’s Member and partner countries, working together to build long term economic and societal benefit from biotechnology across sectors.

The 2022 EuropaBio National Associations Council (NAC) Summit (France) focuses on how biotech is delivering the industrial strategy through national development.

National Associations, biotech companies, policy makers and others will discuss the commercial pathways for healthcare biotechnology to deliver innovative therapeutics to patients, and for industrial biotechnology to drive economic growth and market development.

NAC Summit outcomes will be key policy and initiative recommendations at national and EU level for the successful societal and economic performance of biotechnology across sectors.

Who should take part? If you support development of the biotech community at national or European level, or are a biotech company of any size, get involved and help debate the key drivers for successful economic delivery.

Agenda
10:00 – Opening session: French presidency priorities for biotechnology
Welcome: Tineke Van hooland, Chair EuropaBio National Associations Council
· Healthcare presidency priorities
· Industrial biotech and bioeconomy priorities

10:20 – Healthcare biotechnology: Innovative therapeutics to patients in Europe
Organisations: European Parliament, Sanofi, Tree Frog Therapeutics, HBio, AseBio, Bio.be, EuropaBio, PTC Therapeutics
Topic 1: Building from Europe’s innovation; transforming research to a sustainable and accessible healthcare
Chair: Ana Sofia Antunes, mabdesign
Company statements: Sanofi, Tree Frog Therapeutics
How do national and EU initiatis and policies help move research advances through to patient uptake? What needs to happen in order to bring momentum and investment into technologies, skills and infrastructure for next generation therapies in Europe?

Topic 2: Innovation and healthcare across borders; Delivering Europe’s strength to all
Chair: Chloé Evans, France Biotech
Company statement: Sanofi, PTC Therapeutics
How does Europe enable cross-border healthcare? The panes discusses the policy, regulatory frameworks and national collaborations that can bring ultimate benefit for European citizens.

11:30 – Break
11:45 – Industrial biotechnology and bioeconomy: Growth and innovation to market
Organisations: Circular Bio-based Europe Joint Undertaking, AFYREN, ITERG & PIVERT & IMPROVE, France 2030, BASF, HollandBio, Remilk, Bio-Base Europe Pilot Plant
Topic 3: Acceleration of business and manufacturing; investment and policy
Chair: Christophe Luguel, IAR
Company statements: AFYREN, BASF
How does Europe ride the wave of manufacturing from biological platforms? The panel discusses national initiatives and EU policies and programmes that enable long term investment into large scale manufacture and ensuring a competitive next generation industrial landscape.

Topic 4: Novel foods; A pathway to market in Europe
Chair: Agnes Borg, EuropaBio
Company statements: BASF, Remilk
Novel foods are a core part of Europe’s future sustainability and competitiveness, offering an opportunity to capitalise on world leading research. The panel will discuss the critical policy and regulatory framework that will enable investment in early stage innovators and for large scale production for European and global market performance.

13:00 – Closing plenary: Looking ahead for European industrial delivery from biotechnology
Chair: Claire Skentelbery, EuropaBio
Chairs and companies from across the sessions discuss key messages from the meeting and make recommendations for policies and initiatives at national and European levels to deliver economic contribution from biotechnology.

13:30 – Close

Speakers
Tomislav Sokol, Member of the European Parliament, EPP, Croatia
Tomislav Sokol was born in Zagreb in 1982. He obtained his first degree in law at the Faculty of Law, University of Zagreb, in 2006, magna cum laude. He then obtained a Masters of Law (LL.M.) specialising in European Union Law at the Katholieke Universiteit Leuven (KUL), Belgium, in 2009, magna cum laude. He defended his PhD at KUL, dealing with free movement of cross-border health care services in the EU and its impact on national health insurance systems in 2014.
He was an Assistant Minister in the Ministry of Science and Education in 2017, after which he became a Member of the Croatian Parliament. He was a Member of the Croatian Parliament until July 2019, when he became a Member of the European Parliament. He is a Member of the Committee on the Internal Market and Consumer Protection (IMCO) and a Substitute Member of the Committee on Regional Development (REGI).
So far, he has published around 20 papers and 1 book on issues concerning EU law, including several articles in European journals, such as the European Law Review and the European Law Journal. He has presented papers at many international conferences and worked on different research projects. Previously, he worked in a legal practice and is currently a Senior Lecturer at the Zagreb School of Economics and Management where he has taught Introduction to European Union and Principles of Law courses since the academic year 2010/2011. He is also an assistant professor at the Catholic University of Croatia where he has taught since the academic year 2016/2017. His areas of professional interest include the law of the European common market, EU health law, competition law, International and European social law and International and European trade law.
Ana Sofia Antunes, Head of International Relations & Scientific Events, MabDesign
Ana Antunes obtained her PhD in Microbiology from the Lisbon University. She has an international career having worked both in research institutions like Institut Pasteur à Paris, or Instituto de Tecnologia Quimica e Biologica (ITQB, Portugal) as well as pharmaceutical companies as Novartis Vaccines & Diagnostics (Siena, Italy). Through her career, she has been involved in the organization of scientific events such as workshops and dedicated conferences. Ana is Head of International Relations & Scientific Events at MabDesign.
Elke Duwenig, Senior Biotechnology Expert Regulatory / Public & Government Affairs, Nutrition & Health, BASF
Dr. Elke Duwenig is an inspiring senior expert, skilled in biotechnology and innovation on agricultural and life science challenges, with passion for sustainable solutions. She is currently active in Regulatory and Government Affairs for Industrial Biotechnology at Nutrition & Health, BASF SE. She was also an expert lead in the Corporate Renewable Raw Material Roadmap at BASF. Elke gives expert guidance for strategies and roadmaps as well as for R&D projects and sales products. She is strongly engaged in legislation and authority work to safeguard biotech products and opening markets together with EuropaBio, EU SFI, FEFANA, AMFEP, and other trade associations and think tanks like BIC, ILSI and AFSI, both in the EU and globally.
Elke studied biology and chemistry at the University of Münster, Germany and Stanford University, USA. She graduated and completed her doctorate in molecular plant physiology at the Institute for Gene-Biological Research (Institut für genbiologische Forschung) IGF, Berlin, and did two postdocs at the Max-Planck Institute in Golm and the University of Freiburg, Germany, before joining BASF.
Denis Chéreau, Chief Executive Officer, ITERG & PIVERT & IMPROVE
Denis Chéreau holds a Ph.D. in microbiology (production of single-cell protein by solid state fermentation).
After 15 years in the production and marketing of enzymes, he moved for 14 years in the starch industry as technical and plant manager in France and the USA.
He is currently general manager of 3 R&D centres : IMPROVE expert in plant based protein, PIVERT expert in green chemistry and biotechnologies and ITERG French institute of oil seeds and plant based fat processing.
Nicolas Sordet, Co-founder & Chief Executive Officer, AFYREN
Nicolas Sordet is co-founder and Chief Executive Officer of AFYREN since 2014. He holds a Master’s degree in Corporate Finance and Financial Markets from the Grenoble Management School.
He put his financial knowledge into practice by holding several positions in Investment banks and Financial Institutions in Switzerland, in the US and in Asia.
He was Deputy Chief Executive Officer of Link Securities from 2006 to 2013, then Private Equity/Venture Capital and Financing Advisor from 2013 to 2014. He has been able to apply his financial expertise and experience for AFYREN development.
Virginia Puzzolo, Head of Programme, Circular Bio-based Europe Joint Undertaking
Virginia holds a doctoral degree in plant ecology and biology. For the last 20 years, she has been developing and implementing the EU research and innovation policies in several EU institutions. Virginia’s previous professional experience includes the European Commission’s Research Executive Agency, the Enterprise Directorate-General of the European Commission, the EU’s Joint Research Centre, and the Italian Research Forest Management Institute.
Ion Arocena Vélez, Director General, AseBio
Ion Arocena joined AseBio, the Spanish Bioindustry Association, in 2016 as general manager. He is a biotechnologist by training and completed his studies with an executive MBA at EOI Business School, Madrid.
He started off at the Technology Transfer Office of the Universidad Autónoma de Madrid, offering Technology Watch services to SMEs. His next position was at Genoma España, a Government Owned Agency promoting the protection of Intellectual Property and the transfer of such results to companies.
From 2006 to 2015, he was part of the funding team of Suanfarma Biotech SGECR, a venture capital firm, specialized in life science, where he was responsible for the evaluation of investment opportunities.
Mathieu Brandibat, National coordinator of the “Recyclability” and “Biosourced” acceleration strategies, France 2030
Mathieu Brandibat is an agronomist. Specialized in the management of information systems, he worked within fields such as the valorization of innovation and the utilities. Following a duty at the ADEME (French Agency dedicated to the ecological transition), he is now part of the Prime Minister services (General Secretariat for Investment – SGPI) involved in the national plan “France 2030” dedicated to pave an ambitious way for R&D, innovation and industrialization, as the national coordinator for strategies « recycling and reincorporation of materials » and « Biobased products and industrial biotechnologies – sustainable fuels”.
Wieteke Wouters, Programme Director, HollandBIO
Wieteke Wouters is program director of HollandBIO, the Dutch biotech industry association. HollandBIO’s mission is that biotech is able to contribute maximally to a sustainable and healthy society. With the motto “challenge the status quo”, HollandBIO takes on the obstacles that stand in the way of the sector’s innovative frontrunners.
Prior to joining HollandBIO, Wieteke worked at a consultancy firm specialized in health and sustainability. Wieteke began her career at a Leiden based biotech start-up. Wieteke graduated in Biomedical Sciences at Utrecht University and specialized in Science and Business Management.
Kevin Alessandri, PhD, Co-founder and CTO, TreeFrog Therapeutics
Initially trained in biophysics at the Ecole Normale Supérieure, Kévin Alessandri completed in 2013 a PhD thesis on cell encapsulation technologies at the Institut Curie, France. He then continued his rexearch at the University of Geneva, Switzerland, where he met Maxime Feyeux, an expert in pluripotent stem cell biology. Together, they invented a biomimetic cell culture technology – C-Stem – allowing for the mass-production of cell therapies. Alessandri and Feyeux co-founded TreeFrog Therapeutics in 2018, with the aim of providing access to safer, more efficient and more affordable cell therapies to millions of patients. Following a recent $75M Series B financing, Kevin Alessandri will move to Boston, USA, in September 2022 to lead the newly created U.S. subsidiary of TreeFrog Therapeutics.
Chloe Evans, Market Research Manager & International Relations, France Biotech
Chloé Evans is currently Head of Market Research and International Relations at France Biotech. Since 2016, she has been coordinating market research and industry publications for the association, conducting policy impact assessments and business intelligence. She also helps support and coordinate some of France Biotech’s working groups and the Association’s actions on new policies and advocacy for healthcare and biotechnology industries. Since 2019, she oversees international relations with both European and global associations and stakeholders. Prior to joining France Biotech, Chloé worked in strategy consulting for the healthcare sector at Bionest Partners and then with D&Consultants where she worked on various strategy and marketing projects for technology transfer offices, pharma and biotech companies.
Ms. Evans holds a degree in Biochemistry (BSc) from the University of Manchester (UK) and a Master’s degree in European Business and Management from ESCP Europe Business school (London/Paris).
Frédéric Druck, Managing Director, essenscia wallonia /brussels – Secretary General, bio.be/essenscia
Since September 2016, Frédéric Druck (55) is the Secretary General of bio.be/essenscia, the association of companies active in Belgian life sciences and biotechnologies industry. Frédéric is also Managing Director of essenscia wallonia and of essenscia brussels, the regional associations of the Belgian federation for chemistry and life sciences industry “essenscia”. Finally, he is chairing the Board of aptaskil, the training center for chemistry and life sciences in Wallonia as well as the Board of the EU Biotech Campus, a multi training operators platform that is part of the Belgian Recovery Plan.
Frédéric joined essenscia after spending almost 10 years at BioWin, the health cluster of Wallonia (Belgium) where he mainly developed international partnerships with biotech clusters from the US, China and Europe. During this period, he used to Chair the Council of European Bio Regions (CEBR) and the European Diagnostic Clusters Alliances (EDCA).
Frédéric did his whole career in Public Relations and Public Affairs positions in the biopharma industry as well as in sector-related associations.
Liam Sharon, Head of food technology, Remilk
MSc food molecular biology from the Hebrew university Jerusalem, Israel. BSc Food science, technology and Management from Heriot Watt University Edinburgh, Scotland. More than 15 years’ experience in the food industry with emphasis on dairy and product development. Joined Remilk as a Head of food R&D one year ago
Hendrik Waegeman, Head of Business Operations, Bio Base Europe Pilot Plant
Hendrik Waegeman obtained a master degree in biochemical engineering at Ghent University (2007) and holds a PhD in Applied Biological Sciences-Chemical Engineering (2011), also obtained at Ghent University. During his doctoral research he metabolically engineered Esherichia coli to improve recombinant protein production. During his post-doctoral research, Hendrik Waegeman was involved in a number of projects that focused on the fermentative production of specialty carbohydrates. He is also a co-founder of the company Inbiose NV, founded in 2013, which develops fermentatively produced specialty carbohydrates such as human milk oligoscaccharides. In 2012 he was guest lecturer at the University of Incheon, South-Korea where he lectured a course on Metabolic Engineering and Modelling of Micro-organisms. Since 2012, he has a position at Bio Base Europe Pilot Plant, a multi-purpose pilot facility in the Port of Ghent in Belgium where he has worked as Head of Business Development and is now Head of Business Operations.
Hendrik is also board director of Inbisoe NV, Bio.be (the cluster of Belgian biotech companies) and Biobased Industries Consortium (BIC, the private partner in the joint undertaking Horizon2020-BBI and the upcoming joint undertaking CBE (Circular Bio-based Europe).
Stamatiki Kritas, Research & Development, Innovation Management, HBio Cluster
Christophe Luguel, Head of International Affairs, Cluster Industries & Agro-ressources (IAR)
Agnes Borg, Industrial Biotechnology Director, EuropaBio

Should you encounter any issues with the reception of the confirmation email, please contact Martina CILIA (m.cilia@europabio.org).

REGISTER HERE

ESAB Webinar: Enzyme Engineering
2022-02-25 10:00 - 12:00
Preliminary Programme / Speakers

10:00: Enzyme evolution for efficient biosynthesis of biofuel and medicine

Prof. Dr. Yan FengDistinguished Professor and Vice Dean, School of Life Science and Biotechnology, Department of Biochemistry and Molecular Biology, Shanghai Jiao Tong University, Shanghai, China

10:30: Biomolecular engineering with microbial transglutaminase

Prof. Dr. Noriho KamiyaDirector, Division of Biotechnology, Center for Future Chemistry (CFC), Department of Applied Chemistry, Faculty of Engineering, Kyushu University, Japan

11:00: Surfing the wave of oxyfunctionalization chemistry by engineering fungal unspecific peroxygenases

Prof. Dr. Miguel AlcaldeDepartment of Biocatalysis, Institute of Catalysis, Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain

11:30: Redesign of oxidative enzymes for the biocatalytic valorisation of biomass

Prof. Dr. Marco W. FraaijeProgramme Director MSc Biomolecular Sciences, Molecular Enzymology Group, University of Groningen, Groningen, The Netherlands

Flyer

Abstracts and Short Bios of the speakers

REGISTER HERE

Introducing the Innovative Health Initiative: Europe’s new partnership for health
2022-01-26 10:30 - 13:00
The Innovative Health Initiative (IHI) aims to build on the successes of the Innovative Medicines Initiative (IMI) and will hold a launch event in a virtual setting on Wednesday, January 26th, from 10:30am to 1:00pm.

The event will be broken up into two sessions:

In the first session, IHI Executive Director Dr Pierre Meulien will present IHI and explain why we are launching a new European partnership for health. He will also describe what’s new compared to the Innovative Medicines Initiative (IMI), and what will stay the same. IHI staff will then present opportunities for stakeholders to get involved in IHI, for example by applying to become a member of the IHI Science and Innovation Panel (SIP), or by becoming an expert evaluator. They will also offer a preview of the draft topics under consideration for inclusion in the first IHI call for proposals.

The second session will feature a high-level discussion during which representatives of the IHI partners, namely the European Commission, COCIR, EFPIA, Vaccines Europe, EuropaBio and MedTech Europe, will present their vision for IHI.

Both sessions will include time for questions from participants.

More info here

How can stronger IP in EU Free Trade Agreements boost productivity and economic growth in Europe?
2022-01-11 10:30 - 11:45
You are invited to join a virtual event seeking to discuss the economic and societal value of intellectual property rights (IPRs) for Europe.

How do IPRs in EU Free Trade Agreements (FTAs) support EU strategic resilience and global competitiveness in a post-COVID world? What are the concrete benefits of robust IPRs for EU member states? How important is IP for innovation, in particular for the green and digital societal transformations? Why should IPRs be given a more prominent role in EU policy making, especially when it comes to EU FTAs? These are some of the questions that our guest speakers will address during the panel discussion.

Following the presentation of a recent ECIPE report, the speakers will explore how stronger IPR provisions in EU FTAs contribute to EU and EU Member State economic and societal ambitions.

Speakers:

Fredrik Erixon, Director, ECIPEMaria Martin-Prat, Deputy Director – General, DG TRADENathalie Moll, Director General, EFPIALuisa Santos, Deputy Director General, BusinessEurope

If you have any questions or require additional information, please contact ECIPE at events@ecipe.org

We look forward to virtually meeting you on 11 January!

Register

EuropaBio 25th Anniversary | mRNA: A voyage of discovery and celebration
2021-12-13 14:00 - 15:00
The existence of messenger(m) RNA was hypothesized early in the days of DNA breakthroughs in the 1960s, and research from the 1990s started to reveal its potential as a therapeutic tool.

mRNA became a household name in 2020 and 2021 as arguably the most important global breakthrough of recent years, with its ability to create a specific proteins underpinning vaccine development in response to Covid-19.EuropaBio is delighted to host the final event of its 25th Anniversary programme with a focus on the story of mRNA. Its first steps into commercial development, challenges to bring a vaccine to millions of people and life beyond Covid – the destination for mRNA in oncology and other significant health applications.

We bring together protagonists from across the spectrum, including:• Ingmar Hoerr, CureVac Founder and holder of the first patents associated with mRNA• Stephen Lockhart, Head of EU/AP Vaccines Clinical R&D at Pfizer• Dhaval Patel, Senior Manager, Manufacturing & Technology, Catalent Biologic

8th Biorizon Annual Event on Bio-Aromatics
2021-12-02 09:00 - 17:00
December 2nd, major industrial players, small to medium sized enterprises, government officials and research and technology organisations from all over the world will join Biorizon Shared Research Center to discuss the latest progress in the field of bio-aromatics and to elaborate on opportunities to accelerate biobased business together. Biorizon invites you to join, either on-site in Rotterdam, or remotely.

Over the past years, this event has evolved into a must-attend event for anyone who’s interested in renewable aromatics. Last edition attracted 308 participants from 29 countries that engaged in 163 matchmaking sessions.

What to expect from this year’s hybrid annual event on 2 December:

Short, interactive plenary presentations that feature the progress that Biorizon has made in the scaling up of the production of bio-aromatics with premium properties. Plus a keynote speech of a major brand owner you don’t want to miss (t.b.c.).By popular demand, we have maximized the opportunity to arrange matchmaking sessions that can be scheduled as from now. Meet representatives of the entire bio-aromatic value chain from all over the world!

EFIB 2021 | Vienna Statement Launch
2021-11-30 14:00 - 15:15
The ‘EFIB 2021 Vienna Statement’ marked the launch of an annual call to action from EuropaBio members, with policy asks and actions critical in the short term for Europe’s delivery of a bioeconomy.

Developed through 2021 and published at EFIB in Vienna, the statement includes:• Next generation Europe: An urgent call to action• Industrial biotechnology: Proving its value to society, environment and economy• The clock is ticking for European climate and competitive ambitions• Time is now – EFIB Vienna Statement requests for modernisation of regulation and policy, Education and awareness and financing innovation

Moderator:

• Dr Claire Skentelbery, Director General, EuropaBio

Speakers:

• Stefan Buchholz, Senior Vice President R&D Nutrition & Care, Evonik

• Elke Duwenig, Senior Biotechnology Expert Regulatory / Public & Government Affairs, Nutrition & Health, BASF

• Jim Philp, Science and Technology Analyst, OECD

• Video message by Simone Schmiedtbauer, Member of the European Parliament, Group of the European People’s Party, Austria
• Video message by Virginijus Sinkevičius, European Commissioner for Environment, Oceans and Fisheries

We invite you now to join us for the wider launch of the EFIB Vienna Statement – to set the challenge for Europe and discuss what this means for policy, regulation, investment and innovation.

Join us on 30 November at 14:00 CET and be part of the conversation in the 12 months until the next EFIB conference in Vilnius, Lithuania, October 2022.

Register Here

16th European Bioplastics Conference 2021
2021-11-30 08:00 - 2021-12-01 17:00
The European Bioplastics Conference, taking place from 30 November to 1 December 2021 in Berlin, is the leading business and discussion forum in Europe for the global bioplastics sector. With more and more brands and manufacturers embracing the potential of biopolymers, and with policy makers increasingly streamlining their efforts to create frameworks that benefit the growth of sustainable bio-industries, this is the time to put bioplastics on top of the agenda of a bio-based circular economy in Europe and beyond. The 16th conference edition will focus on the latest innovations in bio-based and biodegradable plastics, the current political landscape as well as on environmental aspects, and opportunities for growth.

HealthDay.si Conference 2021: Biotech Meets Digital
2021-11-18 09:00 - 15:00
Biotechnology and digital are getting closer. Due to the high development of both segments, Slovenia has a great global opportunity in this convergent field of medicine. Can good experiences from the digital healthcare ecosystem be linked to biotechnologies? Can we create something in this space that could be globally relevant? Can a new “digital Krka” or a new “digital Lek” be created in this area?

In this year’s HealthDay.si conference we will focus on the digitization of biotechnological solutions related to medicine and health, with emphasis on diagnostics, advanced cell and gene therapies.

Selected speakers, including international experts and CEOs of established companies, will share their expertise and touch upon additional topics starting with financing growth by a seed round, PPPs in health/research and ranging to secondary use of health data, prevention, value-based health system, ATMP therapies, digitalization of genomic data and artificial intelligence.

Rare Conversations Conference | European Rare Disease Ecosystem: A Collaborative Path Forward
2021-11-09 14:00 - 18:00
Join the inaugural Rare Conversations Conference aimed at facilitating essential discussion on the future of the rare disease and OMP ecosystem involving leading experts.The event will bring together thought leaders across regulators, payers, patient organizations, research, academia, EU institutions, industry and investors to develop inspiring ideas to advance the future of rare diseases. In four sessions, speakers will cover the entire rare disease and orphan drug value chain from research through to access.Be part of this multifaceted and holistic approach to improving the rare disease ecosystem for the next decade and beyond in the EU through true multi-stakeholder exchange.The event is organized by Alexion in cooperation with the European rare disease patient organisation EURORDIS, the European Joint Programme on Rare Diseases EJP RD, the body for small to medium-sized innovative pharmaceutical, biotechnology and medical technology companies EUCOPE, and the association of the biotech industry EuropaBio.Block your calendar for 9th November from 14.00 – 18.00 CET. More information and the registration link will be shared with you shortly.

About “Rare Conversations”Rare Conversations is an event series organized by Alexion to educate on rare diseases and facilitate multi-stakeholder exchange, tackling timely topics of interest such as the revision of the OMP Regulation. Rare Conversations aims to unite and engage the rare disease community, including key stakeholders in Brussels and EU Member States. Since its inception in December 2020, four Rare Conversations have taken place, each in cooperation with a different partner and focused on specific topics, such as COVID and rare diseases, the specificities of research in rare disease, and EU and national value assessment for orphan drugs. People with rare diseases always stay at the centre of our activities and are part of every event.

2nd Hellenic Biocluster Forum
2021-11-04 08:00 - 2021-11-05 17:30
HBio is a strong innovation moderator, connecting and supporting industry and academia partners to develop innovative and impact science. The Hellenic Biocluster delivers connectivity to the global science and technology frontiers for more than 65 partners, with the vision to continue being a catalyst, adding value to the innovation performance of its’ partners and Greece as a whole.

HBio is pleased to host the 2nd Hellenic Biocluster Forum in Athens, on November 4-5, 2021. EuropaBio’s Director-General, Dr. Claire Skentelbery, will speak at the panel “Vision for Life Sciences and Biotechnology for a Healthy and Sustainable EU”, on November 4, from 09.00 to 09.45 CET.

EuropaBio 25th Anniversary | Healthy planet, Healthy people
2021-10-25 13:00 - 14:15
At the time of the 25th Anniversary of EuropaBio, we would like to look to the future and the green transition that will shape healthcare for us all.

This open webinar aims at kicking off the discussion on pathway for green transition in the biopharmaceutical ecosystem. This biopharmaceutical ecosystem has a complex and resource intensive profile, from research, to manufacture through to use and disposal of highly regulated therapeutics.

Change is Now, with companies investing in long term product and process design for carbon neutrality and circularity. Join us to hear from pharma, sustainable pharmaceutical engineering, policy makers, consumers and the European Commission on the priorities, actions and outcomes to ensure that healthy people go hand in hand with a healthy planet.

Moderator:

Dr Claire Skentelbery, Director General, EuropaBio

Speakers:

Carmen Laplaza, Head of Unit, Health Innovations and Ecosystems, DG Research and Innovation

Montserrat Montaner, Chief Sustainability Officer, Novartis

Jutta Paulus, Member of the European Parliament, Group of the Greens, Germany

Dr Wouter De Soete, Manager Centre of Excellence in Sustainable Pharmaceutical Engineering & Manufacturing, University of Ghent

Kristin Schreiber, Director, Directorate Ecosystems: Chemicals, Food, Retail, Health, DG Grow, European Commission

REGISTER HERE

EuropaBio Patient Bio-Forum | European Reference Networks: challenges, achievements and opportunities
2021-10-19 11:00 - 12:30
EuropaBio, the European Association for Bioindustries, is proud to continue our platform for engaging patient and industry alike on pertinent healthcare debates: the Patient Bio-Forum. In this edition the focus will be on the impact of European Reference Networks (ERNs).

With an aim to facilitate discussion between patients and medical professionals across the EU, ERNs tackle rare disease head on. Creating a pooled, virtually accessible network of experts, ERNs demonstrate the power of collaboration in diagnosis complex and rare diseases. With the first ERNs having started in 2017, we anticipate a periodic evaluation during 2022/23. Similarly, this year the Commission have undertaken an evaluation of the Cross-border Healthcare Directive which establishes the legal basis of ERNs.

Against a backdrop of societal change, the EuropaBio Patient Bio-Forum convenes this October with a panel of experts representing patient, industry, EU and Member State perspectives on the challenges, achievements and opportunities the ERNs present.

AGENDA

Welcome and introduction (5 mins)

Nicola Bedlington (Moderator)

Panel Discussion (45 mins)

Ingunn Westerheim, President, OIFE – Osteogenesis Imperfecta Federation Europe;Dr. Birute Tumienė, clinical geneticist at the Centre for Medical Genetics and the Coordinator for Competence Centres in Vilnius University Hospital Santaros Klinikos, ERN Board Member on behald of LithuaniaDr. Jose A. Valverde, Policy Officer, Unit B.3 – European Reference Networks and Digital Health, DG SANTE, European Commission;Assoc. Prof. Dr Till Voigtländer, Department of Neuropathology and Neurochemistry University of Vienna, Eurordis Black Pearl Awardee 2019Dirk Vander Mijnsbrugge, Vice President Medical Affairs Lead Rare Diseases International Developed Markets, Pfizer

Biobreak/Slido Poll (5 mins)

Moderated Q&A (35 mins)

From the audience, submitted via chat function.

Closing remarks

EU4Health 2021 Work Programme | Info Session on HERA Procurement Calls
2021-10-14 10:00 - 12:00
The European Health and Digital Executive Agency (HaDEA) with the support of the European Commission organizes an info session to present three HERA’s public procurement calls launched under the EU4Health work programme 2021 (C(2021)4793 final):– HADEA/2021/OP/0005 – A Study on Bringing AMR Medical Countermeasures to the Market– HADEA/2021/OP/0006 – Feasibility Study on Stockpiling of Medical Countermeasures in the Area of AMR– HADEA/2021/OP/0009 – Feasibility Study, Design and Prototype Development for a Mapping Platform on COVID-19 Therapeutics in the EU

European Forum for Industrial Biotechnology & the Bioeconomy (EFIB)
2021-10-05 10:00 - 2021-10-07 19:00 | Vienna (Austria), Vienna, Austria
Save the date for this 14th edition!EFIB is the market leading annual event in Europe for Industrial Biotechnology and the Bioeconomy. Visit the dedicated website to secure your place today.

https://efibforum.com/

The small companies changing the world: Meet the science and business of sustainability
2021-09-30 14:00 - 15:00
With the Green Deal, the EU has set an ambitious strategy towards climate neutrality, transitioning to a circular economy and a more sustainable food system. Many aspects of our lives must change to achieve these ambitions: a reduction in only high profile targets, such as transport, will not be enough. Our food, cosmetics, clothes, and other products and consumables across our lives need to get leaner and greener and biotechnology solutions can contribute towards responding to this need.

Confirmed speakers:

Juan Medina, Co-Founder and CEO Kaffe BuenoTaichi Ochi, Senior Business Developer, EV BiotechCyrille Pauthenier, CEO Abolis

Join us to find out how small companies across Europe are rising to the challenge to innovate for our sustainable futures.

Slides

REGISTER HERE

Investing in healthcare - How can the revision of the general pharmaceutical legislation better attract investors in the future?
2021-09-29 12:00 - 13:30 | Invest Europe
The evaluation and revision of the general pharmaceutical legislation is the opportunity to create a future-proof, patient-oriented and leading life science and biotechnology sector in the EU.

The first aim of this initiative should be to regain EU’s global leadership as a home for R&D and cutting-edge industry to secure high-quality care for citizens at affordable levels.

New biotechnology-derived vaccines and treatments have helped to tackle numerous life-threatening illnesses. Targeted treatments, like cell and gene therapies, and new mRNA platforms are paving the way for future treatments. COVID-19 has shown that only science-based and high-risk research embedded in a strong life science industry ecosystem can bring the lasting solutions to health challenges.

Emerging biopharmaceutical companies account for over 70% of the research pipeline contributing to a vibrant sector. The EU biotech sector, mostly made up of SMEs, relies on robust IP and targeted incentives that enable companies to raise risk capital, with the prospect of remaining unprofitable for years. It is due to these set of incentives that the EU has retained its capability to produce breakthrough innovation. To keep pace with the rest of the world, future incentives should reflect the economic challenges of developing health innovation.

Join us to find out how investing in R&D for innovative medicines and treatments is essential to support a competitive European biotechnology industry.

Confirmed speakers::

Juozas OLEKAS, Member of the European Parliament, S&D, Lithuania

Stefan Gijssels, SEBOIO Health Policy Consulting and Co-founder of digestive Cancer Europe

Ingrid Maes, Co-founder of Inovigate, 25 years of experience in Life Sciences Expertise in New Product Development and Market Introduction

Isabelle Schubert, Global Head IP Strategy at Novartis

Oskar Slotboom, General Partner at BGV (BioGeneration Ventures)

Slides

REGISTER HERE

Biotechnology for society - Turning science into a sustainable and healthy world
2021-09-27 15:30 - 17:00
EuropaBio’s launch meeting for Biotech Week will share how science finds its way to an end use, whether it is a new medicine, or a product developed using new scientific processes.

Europe sets the global standard for consumer and environmental protection. This translates into a regulatory framework for different sectors through which novel products must pass before they can be used in Europe. The European Medicines Agency (EMA) and the European Food Safety Authority (EFSA) are the gateway for new products and play a critical role in how Europe innovates safely.

It can be complicated, particularly for new science. So how does Europe deliver innovation to benefit patients and our planet whilst ensuring the high standards and safety that we expect?

The Covid response from regulators demonstrated how Europe can be agile and rapid for the vaccines that are now helping Europe restore a safe and open society. Our launch event for Biotech Week brings together the community that develops products from science to consumers, highlighting how we can evolve our regulatory systems help develop safe societies and a competitive Europe.

Confirmed speakers:

Ana Maria Bravo, Director of Government Affairs, IFFWolfgang Gelbmann, Senior Scientific Officer, Nutrition Unit, EFSADamian Gilkerson, CSL Behring Executive Director Therapeutic Area EU, Commercial Operations EuropeEmmanuelle Voisin, CEO Voisin Consulting Life Sciences

Join us to find out how science reaches its target and help EuropaBio kick start a week dedicated to the explanation and celebration of biotechnology.

REGISTER HERE

10th International Trade Show & Partnering
2021-09-27 12:00 - 2021-10-01 12:00 | Auditorium & Trade Show Centre, Plaza del Baluarte s/n, 31002, Pamplona, Spain
The largest biotech event country based event in Europe

BIOSPAIN is the largest biotech event organized by a national bioindustry association in Europe and one of the largest in the world by the number of one-to-one meetings (+3.300) and companies participating (+773). 34% of our delegates came from outside of Spain.

Why Spain?

In 2018 there were 751 dedicated biotechnology enterprises in Spain (+5,33%), according to data in the AseBio Report 2019. Biotech companies have generated more than €8.2 billion in income, roughly 0.7% of the national total. The biotechnology sector was responsible for more than 105,000 direct, indirect and induced jobs, which is 0.6% of national employment. Over 27,000 of these jobs were people employed directly by biotech companies. Biotechnology activities are at the top of rankings on production growth of economic activities for 2018, up 10.1%.”

EuropaBio Members can benefit of a 10% discount on the price. Please liaise with Martina Cilia (m.cilia@europabio.org) to receive detailed information on the discount code.

Register here

European Biotech Week 2021
2021-09-27 08:00 - 2021-10-03 08:00
The European Biotech Week celebrates biotechnology, an innovative and vibrant sector launched by the discovery of the DNA molecule back in 1953. The first European Biotech Week that took place in 2013 marked the 60th anniversary of this pivotal moment in history.

EFIB Pre-event webinar
2021-09-21 14:30 - 15:30
Sustainability in industrial biotech innovations: life cycle assessment and beyond

Sponsored by DSM

Get ready for EFIB 2021 by attending the kick-off webinar “Sustainability in Industrial biotech innovations: Life Cycle Assessment and beyond”, which will take place on Tuesday 21 September 2021 from 14.30 – 15.30 CET.

Sustainability is the drive and purpose behind most industrial biotech innovations. But how to incorporate it in the innovation process? How to assess it, measure it, and use it for decision making? During this webinar we will explore:

• How well-established tools like Life Cycle Assessment are being used in industrial biotech innovations

• What are novel tools and methodologies relevant for the sustainability assessment of industrial biotech

• How corporates, start-ups and academia use these tools in their innovation process

This kick-off webinar by EuropaBio is co-hosted by Planet B.io, the open innovation hub for industrial biotechnology, located at the Biotech Campus Delft in The Netherlands.

Moderator:

• Maria Cuellar-Soares | S&T Officer, Planet B.io

Speakers:

• Ulla Létinois | Senior Scientist, Sustainable Chemistry, DSM

• Yang Xiang | Senior Corporate LCA Expert, DSM

• Cristina Prat | Co-founder, FUL Foods

• John Posada | Assistant Professor in Biotechnology and Society, TU Delft

Slides

Participation for this webinar is free of charge, but registration is required.

REGISTER HERE

German Biotechnology Days
2021-09-20 09:00 - 2021-09-21 17:00 | BIO Deutschland, Schützenstraße 6a, Berlin, D-10117, Germany
Germany’s largest biotech event, the German Biotechnology Days 2021 (Deutsche Biotechnologietage, DBT), will take place on 20th and 21st September in Stuttgart. With over 800 participants, the event is regarded as the German class reunion for biotechnology. The DBT brings together entrepreneurs with scientists and partners from politics, funding institutions and administration.

In plenary sessions and numerous symposia, top-class speakers present and discuss the diverse fields of application and the potential of biotechnology, from health research to bioeconomy, from medicine to industrial production and plant breeding. Exchange and networking traditionally play a major role at the DBT. The big evening event on the first day of the conference is therefore a further highlight. In addition to the conference programme, there will also be a large exhibition.

The German Biotechnology Days are jointly organised by BIO Deutschland and the Council of German BioRegions. The host region for 2021 is STERN BioRegion from Stuttgart. As a partner region, we are looking forward to BioLAGO, the network for the health industry in the Lake Constance region.

About the organizersBIO Deutschland e. V., the industry association of the German biotechnology industry, and the Council of German BioRegions have been jointly organising the German Biotechnology Days since 2010. The forum for the German biotechnology scene takes place annually at different locations. The regional host of the event is always a bioregion from the Council of German BioRegions, often accompanied by a partner region.

VIRTUAL EVENT

Register Here

Treatment without borders: the EU case for equitable patient access to advanced therapies
2021-09-07 16:00 - 17:00
The EU Pharmaceutical Strategy is looking to improve patients’ access to therapies for challenging and rare conditions. The EU legislation on cross-border healthcare is an important instrument to ensure patient access to the best available care. There is an urgent need to revise this legislation to enable EU patients to access novel advanced therapies and medicines for rare diseases when these are not available in their home country.

EuropaBio’s Advanced Therapies Series continues with a virtual discussion on avenues for enhancing the access of EU patients to novel biotechnology-derived treatments on September 7, 2021, from 16h00 to 17h00 CET.

A patient who is also actively engaged in patient advocacy will explain the value of advanced therapies for rare disease patients and the key challenges they encounter when accessing treatments outside their home countries.

A panel of EU, national, and industry representatives will attempt to put forward solutions for securing equitable access to both specialised centres and to treatment for all EU patients in need. Among others, they will seek to advise on how to tackle the following challenges: some treatment centres being less interested to treat cross-border patients, the need for experience and expertise in rare diseases, approval process and time for cross-border treatment, lack of knowledge or experience of healthcare providers in requesting reimbursement for cross-border treatments, difficulties in approving advanced therapy applications if not reimbursed in the home country, etc.

Moderator

Bernard Grimm, Healthcare Biotech Director, EuropaBio

Speakers

Jana Popova, Executive Committee Member of the European Alliance of Neuromuscular Disorders Associations & EUPATI Patient Engagement Training Coordinator

Brieuc Van Damme, Director-General Healthcare, RIZIV-INAMI

Martin Dorazil, Deputy Head of Unit, DG Health, European Commission

Dirk Vander Mijnsbrugge, Vice President Medical Affairs Lead Rare Diseases International Developed Markets, Pfizer

Irina Grossenbacher, Region Europe Patient Access Director, Novartis Rare Diseases

Tomislav Sokol, Member of the European Parliament, EPP, Croatia

International Conference on Renewable Resources & Biorefineries
2021-09-06 12:00 - 2021-09-08 12:00 | University of Aveiro, Santiago Campus, 3810-193 Aveiro, Aveiro, Portugal
The 17th edition of the International Conference on Renewable Resources & Biorefineries will take place in Aveiro, Portugal from Monday 6 Sept until Wednesday 8 Sept, 2021. Based on the previous RRB conferences, this conference is expected to welcome about 350 international participants from over 30 countries.

Delegates from university, industry, governmental and non-governmental organizations, and venture capital providers will present their views on industrial biotechnology, sustainable (green) chemistry, and agricultural policy related to the use of renewable raw materials for non-food applications and energy supply. The conference further aims at providing an overview of the scientific, technical, economic, environmental, and social issues of renewable resources and biorefineries in order to give an impetus to the biobased economy and to present new developments in this area. The conference will provide a forum for leading political, corporate, academic, and financial people to discuss recent developments and set up collaborations.The three-day international conference will consist of plenary lectures, oral presentations, poster sessions, and an exhibition. Companies and research organizations are offered the opportunity to organize a satellite symposium.

Register here

EU Matchmaking Event on COVID-19 Therapeutics
2021-07-12 09:00 - 2021-07-13 17:00
Building on the experience of the EU Task Force for Industrial Scale-up of COVID-19 vaccines, the European Commission will facilitate cooperation between actors in the supply chain to ensure that available therapeutics are produced in sufficient quantity as soon as possible. In the context of a surge in demand, it remains crucial to ensure the speedy production of current and new therapeutics against COVID-19. To support the industry, the Commission organises the pan-EU matchmaking events for all supply chain actors, so that they find solutions for the bottlenecks encountered.

Medicines for COVID-19 are still in the development phase. Therefore, the objective of the event is to help accelerate the development of new and repurposed medicines for COVID-19 therapeutics, i.e. medicines specifically developed for an indication in treatment of COVID-19, at all stages of COVID-19 disease and mobilise the EU pharma manufacturing capacity for their potential production.

The target group is the entire EU COVID-19 therapeutics value chain starting with researchers and developers, through manufacturing companies and representatives of the hospitals, who apply such therapeutics to their patients. The providers of ancillary functions such as clinical trials services, accessories suppliers (e.g. vials, syringes, tubes etc.), funding providers and public procurers will also be targeted to take part in the event.

The event will take place virtually on 12th and 13th July 2021. 12th July will start with a half-day seminar setting the scene with a welcome by Commissioner Breton and Commissioner Kyriakides.

How to apply?

In order to apply to the event, European companies must comply with the requirements stated in the event’s Call for Expression of Interest. Register until June 25.

Changing Global Ambitions for Biotechnology Innovation: Implications and Drivers for Europe
2021-06-30 12:15 - 13:45
EuropaBio hosts a member-only discussion session looking at ambitions for innovation and business in China, and how this impacts both the EU and US. We are delighted to welcome McKinsey’s China office to the meeting, where they will present an inside look at changing Chinese ambitions for industrial growth from innovation.

Member discussion then focuses on how Europe can deliver its own ambitions in a world where changes beyond its borders will influence success, and how it needs to develop a strong and realistic economic vision for technology from companies and governments.

EuropaBio looks forward to an interesting cross-sector debate amongst Members on the long-term future of Europe as a global competitor and economic performer within the technology space, within profound economic changes world-wide.

All members are eligible to attend and should contact EuropaBio (m.cilia@europabio.org) if they have not yet received an invitation.

BIO Digital 2021 - Rise
2021-06-10 12:00 - 2021-06-18 12:00
Accelerating a BIO-Revolution through global partnerships, collaboration, and thought leadership.

Join The World’s Largest Global Biotech Partnering Experience

From the 10th to June 18th takes place the world’s largest biotechnology partnering event BIO digital 2021, promoted by the Biotechnology Innovation Organization (BIO).

This international convention represents a unique opportunity for companies and institutions related to biotechnology to obtain information of high scientific and financial value, close strategic alliances, obtain financing for their projects and get new clients. The event offers an extensive program that includes academic activities, networking events, company presentations, an exhibition area (considered the largest in the world of those specialized in this sector), seminars and conferences on new trends in biotechnology and innovations, among others.

Register here

EU Healthcare Biotech Policy Priorities for SMEs
2021-06-03 14:00 - 15:00
Join the EuropaBio Healthcare Biotechnology Team for a dive into EU policies that impact your current operations and will shape your future strategies. With the ongoing revision of the basic pharmaceutical legislation and of regulations for medicines for rare and paediatric diseases, SMEs should be planning how they build and grow their businesses, whether within the EU or outside.

About the EuropaBio SME Platform

The SME platform is a community of SMEs across all sectors in Europe, supported through regular online meetings around EU-level topics that impact commercial biotechnology and represented to EU stakeholders.

REGISTER HERE

Global Access to Innovations in Healthtech (GAINH) Summit
2021-06-02 09:00 - 2021-06-03 17:00 | VIRTUAL, Veerstraat 37, Hilversum, 1211 HJ, Netherlands
The Global Access to Innovations in Healthtech Summit is a biennial EXCITE International summit, a Canada based not-for-profit initiative. The 2021 edition will be organized in collaboration with HI-NL, a Dutch organization.

GAINH 2021 will be the first edition taking place in Europe.

The biennial summit has a unique approach that engages industry, payers, health systems, expert end-users and patients across the full pathway, from innovation to adoption, bringing these technologies to market with greater certainty and at a lower cost.

Together with HI-NL, EXCITE International will bring the European and American markets together to accelerate the pathway from innovation to adoption.

About the organizers

EXCITE International and Health Innovation Netherlands (HI-NL) closely collaborate to work towards the common goal of helping innovative medical technologies become accessible to patients, civilians and care providers through a more timely and streamlined process of evaluation, market access, implementation, adoption and reimbursement.

This is achieved by ensuring that all relevant stakeholders who are involved in the life cycle of medical technology, are as early as possible involved in this process. Both organizations are focused on changing the landscape of the medical technology space and believe that innovative ideas that are transformed into medical technological innovations, have the power to shift the patient, civilian and care provider experiences.

Through their collaboration, EXCITE International and HI-NL are creating the bridge between the North American and European medical technology sectors, where stakeholders and their experiences can easily be exchanged.

(GAINH 2021 is organized by Hyphen Projects, a specialized project office that initiates, develops and organizes career fairs, networking events, websites and other formats for the Life Sciences and related sectors).
